Área restringida

La información contenida en esta página está destinada a veterinarios y/o profesionales de salud animal con capacidad de prescripción y/o dispensación de medicamentos.

– Confirmo que soy veterinario o profesional de salud animal.

– Entiendo que la información disponible en esta página se refiere exclusivamente a productos y autorizaciones en España. La información en otros países, debo consultarla a través de los medios oficiales disponibles en el destino específico o con el Departamento de Exportación.

 Antibacterial for injection, Antibacterial / quinolone for injection

Print Friendly, PDF & Email

Enrosyva 100 mg/ml solution for injection

Treatment of respiratory tract infections. Treatment of acute severe mastitis. Treatment of gastrointestinal tract infections. Treatment of septicaemia. Treatment of acute arthritis.

1. Warning

The information available on this page complies with the legislation and texts in vigour in Spain. For all other countries, please refer to the specific local information or contact our Export Department for more information.

*The content of this page is purely informative. For a correct use of the products, please refer to the indications in the Summary of product characteristics..

Quick product information

Active ingredient(s)Route of administrationWaiting timePackaging

Enrofloxacin

Cattle: intravenous or subcutaneous administration

Pigs: intramuscular administration

Cattle: Following intravenous administration: Meat: 5 days Milk: 3 days Following subcutaneous administration: Meat: 12 days. Milk: 4 days. Pigs: Meat: 13 days.

Box with 1 glass vial of 100 ml

Polypropylene vial of 250 ml

Country Availability

Greece, Italy, Poland, Portugal, Spain.

If your country is not listed, please contact our export team.

Contactar

Active ingredient(s)

Enrofloxacin 100 mg /ml

Indications

Cattle
Treatment of respiratory tract infections caused by strains of Pasteurella multocida, Mannheimia haemolytica and Mycoplasma spp. Susceptible to enrofloxacin.
Treatment of acute severe mastitis caused by enrofloxacin-susceptible strains of Escherichia coli.
Treatment of gastrointestinal tract infections caused by enrofloxacin susceptible strains of Escherichia coli.
Treatment of septicaemia caused by enrofloxacin-susceptible strains of Escherichia coli.
Treatment of acute mycoplasma-associated arthritis caused by enrofloxacin-susceptible strains of Mycoplasma bovis in cattle under 2 years of age.

Pigs:
Treatment of respiratory tract infections caused by enrofloxacin-susceptible strains of Pasteurella multocida, Mycoplasma spp. and Actinobacillus pleuropneumoniae. Actinobacillus pleuropneumoniae.
Treatment of urinary tract infections caused by enrofloxacin-susceptible strains of Escherichia coli.
Treatment of post-partum dysgalactia syndrome (PDS) / mastitis, metritis and agalactia syndrome (MMA) caused by enrofloxacin-susceptible strains of Escherichia coli and Klebsiella spp.
Treatment of gastrointestinal tract infections caused by enrofloxacin susceptible strains of Escherichia coli.
Treatment of septicaemia caused by enrofloxacin-susceptible strains of Escherichia coli.

Contra-indications

Do not use in case of known hypersensitivity to fluoroquinolones or to any of the excipients.

Do not use in growing horses because of possible damage to articular cartilage.

Special precautions

When using this veterinary medicinal product, the official recommendations on the use of antimicrobials should be taken into account.

Fluoroquinolones should be reserved for the treatment of clinical conditions which have responded poorly, or are expected to respond poorly, to other classes of antimicrobials.

Whenever possible, fluoroquinolones should be used after performing a sensitivity

Use of the product including use deviating from the instructions given in the SPC may increase the prevalence of bacteria resistant to enrofloxacin and may decrease the effectiveness of treatment with other fluoroquinolones due to cross-resistance.

Posology

Cattle

5 mg of enrofloxacin/kg bw, corresponding to 1 ml/20 kg bw, once daily for 3-5 days.

Acute mycoplasma-associated arthritis, caused by enrofloxacin-susceptible strains of Mycoplasma bovis

in cattle under 2 years of age: 5 mg of enrofloxacin/kg bw, corresponding to 1 ml/20 kg bw, once daily for 5 days.

The veterinary medicinal product can be administered by slow intravenous or subcutaneous administration.

Acute mastitis caused by Escherichia coli: 5 mg enrofloxacin/kg bw, corresponding to 1 ml/20 kg bw, by slow intravenous injection once daily for two consecutive days.

The second dose may be administered by the subcutaneous route. In this case, the withdrawal period following subcutaneous injection applies.

No more than 10 ml should be administered at one subcutaneous injection site.

Pigs

2.5 mg of enrofloxacin/kg bw, corresponding to 0.5 ml/20 kg bw, once daily by intramuscular injection for 3 days.

Alimentary tract infection or septicaemia caused by Escherichia coli:5 mg of enrofloxacin/kg bw, corresponding to 1 ml/20 kg bw, once daily by intramuscular injection for 3 days.

Inject into the neck, at the base of the ear.

No more than 3 ml should be administered at one intramuscular injection site.

Waiting time

Cattle:

Following intravenous administration:

Meat: 5 days

Milk: 3 days

Following subcutaneous administration:

Meat: 12 days

Milk: 4 days:

Pigs:

Meat: 13 days.

Packaging

Box with 1 glass 100 mL vial

Polypropylene vial of 250 ml